Personalis Study Advances Breast Cancer Treatment Monitoring
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology....
Tag : breast cancer
Millions at Risk: Komen Speaks Out Against House Reconciliation Bill
Breast cancer patients could lose coverage, face delays in critical care Susan G. Komen, the world’s leading nonprofit breast cancer organization, is deeply troubled by...
ENHERTU® + THP Pre-Surgery Shows Significant HER2+ Response
Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement...
New Data Show Positive Impact of Oncotype DX® on Patient Care
Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced the presentation of new data further reinforcing the utility of its Oncotype DX...
OS Therapies Gets Patent Allowance for OST-HER2 Manufacturing
Patent Term Adjustment will provide market exclusivity in the United States into 2040 for all therapeutic indications OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology...